{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:42:20Z","timestamp":1791229340583,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1097\/md.0b013e3181630835","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T01:43:46Z","timestamp":1236217426000},"page":"10-20","source":"Crossref","is-referenced-by-count":97,"title":["Scleromyxedema"],"prefix":"10.1097","volume":"87","author":[{"given":"Marissa","family":"Blum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick M.","family":"Wigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Hummers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210226","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00005792-200109000-00005","article-title":"The neurologic complications of scleromyxedema.","volume":"80","author":"Berger","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"R2-2-20210226","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/archderm.140.3.277","article-title":"Thalidomide as a potential treatment for scleromyxedema.","volume":"140","author":"Caradonna","year":"2004","journal-title":"Arch Dermatol"},{"key":"R3-2-20210226","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0190-9622(96)90082-1","article-title":"Multiple periorbital cutaneous myxomas progressing to scleromyxedema.","volume":"34","author":"Craig","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R4-2-20210226","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0190-9622(95)90007-1","article-title":"Scleromyxedema.","volume":"33","author":"Dinneen","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"R5-2-20210226","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2004-12-4870","article-title":"Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation.","volume":"107","author":"Donato","year":"2006","journal-title":"Blood"},{"key":"R6-2-20210226","first-page":"569","article-title":"Fibromes miliaires folliculaires: sclerodemie consecutive.","volume":"37","author":"Dubreuilh","year":"1906","journal-title":"Ann Dermatol Syph"},{"key":"R7-2-20210226","first-page":"1071","article-title":"Complete remission of scleromyxedema following autologous stem cell transplantation.","volume":"137","author":"Feasel","year":"2001","journal-title":"Arch Dermatol"},{"key":"R8-2-20210226","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archderm.1969.01610190057010","article-title":"Scleromyxedema. A dramatic response to melphalan.","volume":"99","author":"Feldman","year":"1969","journal-title":"Arch Dermatol"},{"key":"R9-2-20210226","first-page":"837","article-title":"Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts.","volume":"16","author":"Ferrarini","year":"1989","journal-title":"J Rheumatol"},{"key":"R10-2-20210226","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00005792-198801000-00004","article-title":"Scleromyxedema: a scleroderma-like disorder with systemic manifestations.","volume":"67","author":"Gabriel","year":"1988","journal-title":"Medicine (Baltimore)"},{"key":"R11-2-20210226","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00362184","article-title":"Scleromyxedema; a strange manifestation of myxothesaurodermy..","volume":"199","author":"Gottron","year":"1954","journal-title":"Arch Klin Exp Dermatol"},{"key":"R12-2-20210226","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1126\/science.622555","article-title":"Lichen myxedematosus serum stimulates human skin fibroblast proliferation.","volume":"199","author":"Harper","year":"1978","journal-title":"Science"},{"key":"R13-2-20210226","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/archderm.1979.04010030003002","article-title":"Treatment of scleromyxedema with melphalan.","volume":"115","author":"Harris","year":"1979","journal-title":"Arch Dermatol"},{"key":"R14-2-20210226","first-page":"219","article-title":"Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema.","volume":"39","author":"Helm","year":"1987","journal-title":"Cutis"},{"key":"R16-2-20210226","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood-2006-01-0186","article-title":"Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study.","volume":"108","author":"Illa","year":"2006","journal-title":"Blood"},{"key":"R17-2-20210226","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"R18-2-20210226","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"R19-2-20210226","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0190-9622(86)70104-7","article-title":"Scleromyxedema associated with scleroderma renal disease and acute psychosis.","volume":"14","author":"Kantor","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"R20-2-20210226","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2230.2004.01518.x","article-title":"Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin.","volume":"29","author":"Karim","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"R21-2-20210226","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0190-9622(08)81176-0","article-title":"Successful treatment of scleromyxedema with plasmapheresis and immunosuppression.","volume":"22","author":"Keong","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"R22-2-20210226","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1365-2133.2003.05682.x","article-title":"Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin.","volume":"149","author":"Kulczycki","year":"2003","journal-title":"Br J Dermatol"},{"key":"R23-2-20210226","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1191\/1352458504ms987cr","article-title":"Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a.","volume":"10","author":"Kumar","year":"2004","journal-title":"Mult Scler"},{"key":"R24-2-20210226","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archderm.141.10.1277","article-title":"Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation.","volume":"141","author":"Lacy","year":"2005","journal-title":"Arch Dermatol"},{"key":"R25-2-20210226","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1067\/mjd.2000.104001","article-title":"Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg).","volume":"43","author":"Lister","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R26-2-20210226","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/jid.1953.25","article-title":"Lichen myxedematosus; differentiation from cutaneous myxedema or mucoid states.","volume":"20","author":"Montgomery","year":"1953","journal-title":"J Invest Dermatol"},{"key":"R27-2-20210226","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-4362.2003.01565.x","article-title":"Scleromyxedema revisited.","volume":"42","author":"Pomann","year":"2003","journal-title":"Int J Dermatol"},{"key":"R28-2-20210226","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF01949029","article-title":"Uber eine eigenartige, der Sklerodermie nahestehende Affektion.","volume":"92","author":"Reitmann","year":"1908","journal-title":"Arch Dermatol Syph"},{"key":"R29-2-20210226","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.61.1.59","article-title":"Intravenous immunoglobulins control scleromyxoedema.","volume":"61","author":"Righi","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R30-2-20210226","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/mjd.2001.111630","article-title":"Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema.","volume":"44","author":"Rongioletti","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R31-2-20210226","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"R32-2-20210226","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaad.2004.01.058","article-title":"Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients.","volume":"51","author":"Sansbury","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R33-2-20210226","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1196\/annals.1361.118","article-title":"Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.","volume":"1051","author":"Sapir","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R34-2-20210226","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2133.2005.06710.x","article-title":"Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin.","volume":"153","author":"Shergill","year":"2005","journal-title":"Br J Dermatol"},{"key":"R35-2-20210226","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archderm.1987.01660300108022","article-title":"Plasmapheresis in a patient with scleromyxedema.","volume":"123","author":"Westheim","year":"1987","journal-title":"Arch Dermatol"},{"key":"R36-2-20210226","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0025-6196(11)62956-X","article-title":"Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience.","volume":"80","author":"Wetter","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R37-2-20210226","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1468-3083.2005.01134.x","article-title":"Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins.","volume":"19","author":"Wojas-Pelc","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R38-2-20210226","first-page":"171","article-title":"Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts.","volume":"12","author":"Yaron","year":"1985","journal-title":"J Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0b013e3181630835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:39:33Z","timestamp":1786037973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-200801000-00002"}},"subtitle":["A Case Series Highlighting Long-Term Outcomes of Treatment With Intravenous Immunoglobulin (IVIG)"],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e3181630835","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}